<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:48:51Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8791516" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8791516</identifier>
        <datestamp>2022-01-27</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8791516</article-id>
              <article-id pub-id-type="pmcid">PMC8791516</article-id>
              <article-id pub-id-type="pmc-uid">8791516</article-id>
              <article-id pub-id-type="pmid">35081154</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0262996</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-21-12698</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Head</subject>
                      <subj-group>
                        <subject>Eyes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Head</subject>
                      <subj-group>
                        <subject>Eyes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Ocular System</subject>
                      <subj-group>
                        <subject>Eyes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Ocular System</subject>
                      <subj-group>
                        <subject>Eyes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Clinical Medicine</subject>
                    <subj-group>
                      <subject>Signs and Symptoms</subject>
                      <subj-group>
                        <subject>Hyperlipidemia</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Endocrinology</subject>
                    <subj-group>
                      <subject>Endocrine Disorders</subject>
                      <subj-group>
                        <subject>Diabetes Mellitus</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Metabolic Disorders</subject>
                      <subj-group>
                        <subject>Diabetes Mellitus</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Ocular System</subject>
                      <subj-group>
                        <subject>Ocular Anatomy</subject>
                        <subj-group>
                          <subject>Retina</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Ocular System</subject>
                      <subj-group>
                        <subject>Ocular Anatomy</subject>
                        <subj-group>
                          <subject>Retina</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Eye Diseases</subject>
                      <subj-group>
                        <subject>Retinal Disorders</subject>
                        <subj-group>
                          <subject>Retinopathy</subject>
                          <subj-group>
                            <subject>Diabetic Retinopathy</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Ophthalmology</subject>
                    <subj-group>
                      <subject>Eye Diseases</subject>
                      <subj-group>
                        <subject>Retinal Disorders</subject>
                        <subj-group>
                          <subject>Retinopathy</subject>
                          <subj-group>
                            <subject>Diabetic Retinopathy</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Cardiovascular Anatomy</subject>
                      <subj-group>
                        <subject>Blood Vessels</subject>
                        <subj-group>
                          <subject>Capillaries</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Cardiovascular Anatomy</subject>
                      <subj-group>
                        <subject>Blood Vessels</subject>
                        <subj-group>
                          <subject>Capillaries</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Cardiology</subject>
                    <subj-group>
                      <subject>Cardiovascular Medicine</subject>
                      <subj-group>
                        <subject>Cardiovascular Imaging</subject>
                        <subj-group>
                          <subject>Angiography</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Diagnostic Medicine</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Cardiovascular Imaging</subject>
                        <subj-group>
                          <subject>Angiography</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Imaging Techniques</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Cardiovascular Imaging</subject>
                        <subj-group>
                          <subject>Angiography</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Radiology and Imaging</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Cardiovascular Imaging</subject>
                        <subj-group>
                          <subject>Angiography</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Epidemiology</subject>
                    <subj-group>
                      <subject>Medical Risk Factors</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Capillary density and caliber as assessed by optical coherence tomography angiography may be significant predictors of diabetic retinopathy severity</article-title>
                <alt-title alt-title-type="running-head">Capillary density and caliber in diabetic retinopathy severity</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kushner-Lenhoff</surname>
                    <given-names>Sam</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kogachi</surname>
                    <given-names>Kaitlin</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mert</surname>
                    <given-names>Melissa</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chu</surname>
                    <given-names>Zhongdi</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <xref rid="aff004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shahidzadeh</surname>
                    <given-names>Anoush</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Palejwala</surname>
                    <given-names>Neal V.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <xref rid="aff006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2781-7152</contrib-id>
                  <name>
                    <surname>Wolfe</surname>
                    <given-names>Jeremy</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <xref rid="aff007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Itty</surname>
                    <given-names>Sujit</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <xref rid="aff006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Drenser</surname>
                    <given-names>Kimberly A.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <xref rid="aff007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Capone</surname>
                    <given-names>Antonio</given-names>
                    <suffix>Jr.</suffix>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <xref rid="aff007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dugel</surname>
                    <given-names>Pravin U.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <xref rid="aff006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1441-3378</contrib-id>
                  <name>
                    <surname>Moshfeghi</surname>
                    <given-names>Andrew A.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ameri</surname>
                    <given-names>Hossein</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8433-0485</contrib-id>
                  <name>
                    <surname>Daskivich</surname>
                    <given-names>Lauren P.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="aff008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Ruikang K.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <xref rid="aff004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9767-7920</contrib-id>
                  <name>
                    <surname>Kashani</surname>
                    <given-names>Amir H.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="aff010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Department of Ophthalmology, UW Medicine Eye Institute, University of Washington, Seattle, Washington, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Department of Ophthalmology, Casey Eye Institute, Oregon Health &amp; Science University, Portland, Oregon, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Preventative Medicine, Southern California Clinical and Translational Science Institute, University of Southern California, Los Angeles, California, United States of America</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Department of Biomedical Therapeutics, University of Washington, Seattle, Washington, United States of America</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Department of Ophthalmology, USC Roski Eye Institute, University of Southern California, Los Angeles, California, United States of America</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Retinal Consultants of Arizona, Phoenix, Arizona, United States of America</addr-line>
              </aff>
              <aff id="aff007">
                <label>7</label>
                <addr-line>Associated Retinal Consultants, Oakland University of William Beaumont School of Medicine, Royal Oak, Michigan, United States of America</addr-line>
              </aff>
              <aff id="aff008">
                <label>8</label>
                <addr-line>Ophthalmic Services and Eye Health Programs, Los Angeles County Department of Health Services, Los Angeles, California, United States of America</addr-line>
              </aff>
              <aff id="aff009">
                <label>9</label>
                <addr-line>Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States of America</addr-line>
              </aff>
              <aff id="aff010">
                <label>10</label>
                <addr-line>Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Vavvas</surname>
                    <given-names>Demetrios G.</given-names>
                  </name>
                  <role>Editor</role>
                  <xref rid="edit1" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Massachusetts Eye &amp; Ear Infirmary, Harvard Medical School, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>AHK - NIH Grants: R01EY030564, K08EY027006, Carl Zeiss Meditec (<ext-link xlink:href="https://www.zeiss.com/meditec/us/about-us/contact-us.html" ext-link-type="uri">https://www.zeiss.com/meditec/us/about-us/contact-us.html</ext-link>) (Financial Support); RW - NIH Grant: R01EY028753, Carl Zeiss Meditec (<ext-link xlink:href="https://www.zeiss.com/meditec/us/about-us/contact-us.html" ext-link-type="uri">https://www.zeiss.com/meditec/us/about-us/contact-us.html</ext-link>) (Financial Support); Carl Zeiss Meditec (Patents US8180134B2, US9013555B2, US9759544B2 and US10354378B2), Carl Zeiss Meditec (<ext-link xlink:href="https://www.zeiss.com/meditec/us/about-us/contact-us.html" ext-link-type="uri">https://www.zeiss.com/meditec/us/about-us/contact-us.html</ext-link>) (Consultant), Kowa Inc (<ext-link xlink:href="https://www.kowa-usa.com/about-us.html" ext-link-type="uri">https://www.kowa-usa.com/about-us.html</ext-link>) (Patent). This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>akashan1@jhmi.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>26</day>
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2022</year>
              </pub-date>
              <volume>17</volume>
              <issue>1</issue>
              <elocation-id>e0262996</elocation-id>
              <history>
                <date date-type="received">
                  <day>16</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>10</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2022 Kushner-Lenhoff et al</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Kushner-Lenhoff et al</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0262996.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Purpose</title>
                  <p>To validate retinal capillary density and caliber associations with diabetic retinopathy (DR) severity in different clinical settings.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods</title>
                  <p>This cross-sectional study assessed retinal capillary density and caliber in the superficial retinal layer of 3-mm OCTA scans centered on the fovea. Images were collected from non-diabetic controls and subjects with mild or referable DR (defined DR worse than mild DR) between February 2016 and December 2019 at secondary and tertiary eye care centers. Vessel Skeleton Density (VSD), a measure of capillary density, and Vessel Diameter Index (VDI), a measure of vascular caliber, were calculated from these images. Discriminatory performance of VSD and VDI was evaluated using multivariable logistic regression models predicting DR severity with adjustments for sex, hypertension, and hyperlipidemia. Area under the curve (AUC) was estimated. Model performance was evaluated in two different cohorts.</p>
                </sec>
                <sec id="sec003">
                  <title>Results</title>
                  <p>This study included 594 eyes from 385 subjects. Cohort 1 was a training cohort of 509 eyes including 159 control, 155 mild non-proliferative DR (NPDR) and 195 referable DR eyes. Cohort 2 was a validation cohort consisting of 85 eyes including 16 mild NPDR and 69 referable DR eyes. In Cohort 1, addition of VSD and VDI to a model using only demographic data significantly improved the model’s AUC for discrimination of eyes with any DR severity from controls (0.91 [95% CI, 0.88–0.93] versus 0.80 [95% CI, 0.76–0.83], p &lt; 0.001) and eyes with referable DR from mild NPDR (0.90 [95% CI, 0.86–0.93] versus 0.69 [95% CI, 0.64–0.75], p &lt; 0.001). The transportability of this regression model was excellent when implemented in Cohort 2 for the referable DR versus mild NPDR comparison. The odds ratio of having any DR compared to control subjects, and referable DR compared to mild DR decreased by 15% (95% CI: 12–18%), and 13% (95% CI: 10–15%), respectively, for every 0.001 unit increase in VSD after adjusting for comorbidities.</p>
                </sec>
                <sec id="sec004">
                  <title>Conclusion</title>
                  <p>OCTA-derived capillary density has real world clinical value for rapidly assessing DR severity.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id>
                      <institution>National Institutes of Health</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01EY030564, K08EY027006</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9767-7920</contrib-id>
                    <name>
                      <surname>Kashani</surname>
                      <given-names>Amir H.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100001818</institution-id>
                      <institution>Research to Prevent Blindness</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100002806</institution-id>
                      <institution>Carl Zeiss Meditec AG</institution>
                    </institution-wrap>
                  </funding-source>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9767-7920</contrib-id>
                    <name>
                      <surname>Kashani</surname>
                      <given-names>Amir H.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>NIH Grants to AHK: R01EY030564, K08EY027006, Research to Prevent Blindness (RPB) (<ext-link xlink:href="https://www.rpbusa.org/rpb" ext-link-type="uri">https://www.rpbusa.org/rpb</ext-link>), Carl Zeiss Meditec AG (<ext-link xlink:href="https://www.zeiss.com/meditec/us/about-us/contact-us.html" ext-link-type="uri">https://www.zeiss.com/meditec/us/about-us/contact-us.html</ext-link>), No sponsor/funder played any role in the study design or creation of this manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="3"/>
                <page-count count="12"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>Raw images cannot be shared publicly because of IRB restrictions and the potential to identify subjects using images of the eye. Data are available from the USC Institutional Data Access / Ethics Committee (contact via <email>oprs@usc.edu</email>) for researchers who meet the criteria for access to confidential data.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>Raw images cannot be shared publicly because of IRB restrictions and the potential to identify subjects using images of the eye. Data are available from the USC Institutional Data Access / Ethics Committee (contact via <email>oprs@usc.edu</email>) for researchers who meet the criteria for access to confidential data.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec005">
              <title>Introduction</title>
              <p>Diabetic retinopathy (DR) is one of the world’s leading causes of blindness [<xref rid="pone.0262996.ref001" ref-type="bibr">1</xref>] and its prevalence may be underestimated [<xref rid="pone.0262996.ref002" ref-type="bibr">2</xref>]. Pathologic findings such as microaneurysms, large-vessel dilation [<xref rid="pone.0262996.ref003" ref-type="bibr">3</xref>], and intraretinal hemorrhages are the defining features of DR because they are easily identifiable on fundus imaging and clinical exam. The Early Treatment of Diabetic Retinopathy Severity (ETDRS) is the most widely recognized staging system for DR classification but is primarily a research tool [<xref rid="pone.0262996.ref004" ref-type="bibr">4</xref>]. The current gold standard for clinical diagnosis and management of DR is the International Clinical Diabetic Retinopathy (ICDR) and Diabetic Macular Edema (DME) disease severity scales [<xref rid="pone.0262996.ref005" ref-type="bibr">5</xref>]. All of these scales rely on ophthalmoscopically visible changes in fundus appearance for staging. These macroscopic changes are widely believed to be the end result of many years of cumulative microscopic capillary pathology that are essentially undetectable on ophthalmoscopy [<xref rid="pone.0262996.ref005" ref-type="bibr">5</xref>]. Optical coherence tomography angiography (OCTA)—a commercially available, FDA approved, and noninvasive imaging technique—can capture these subtle capillary changes [<xref rid="pone.0262996.ref006" ref-type="bibr">6</xref>–<xref rid="pone.0262996.ref014" ref-type="bibr">14</xref>]. As a result, it may be useful in evaluating DR severity where access to ophthalmologists is limited and in early stages of disease when invasive fluorescein angiography is neither available nor indicated.</p>
              <p>Vessel skeletal density (VSD) is a dimensionless measure of capillary density representing the total linear length of vessels in an OCTA image normalized to the size of the OCTA image [<xref rid="pone.0262996.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0262996.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0262996.ref016" ref-type="bibr">16</xref>]. This characteristic is known to correlate with DR severity and other systemic risk factors [<xref rid="pone.0262996.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0262996.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0262996.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0262996.ref017" ref-type="bibr">17</xref>]. Vessel caliber as reported by vessel diameter index (VDI) is a related but distinct measure of vessel morphology that has been similarly identified as a useful OCTA metric in DR [<xref rid="pone.0262996.ref007" ref-type="bibr">7</xref>]. VDI is the average width, in pixels, of the vessels in an OCTA image.</p>
              <p>In this study, we determine the robustness of OCTA-derived retinal capillary density and caliber in discriminating DR severity. We then evaluate the transportability, accuracy, and utility of these metrics in two distinct clinical settings [<xref rid="pone.0262996.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0262996.ref019" ref-type="bibr">19</xref>]. In using multiple sites and comparing these metrics to demographic risk factors for diabetic retinopathy [<xref rid="pone.0262996.ref020" ref-type="bibr">20</xref>], we provide an initial assessment of the clinical utility of these OCTA measures.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec006">
              <title>Materials and methods</title>
              <sec id="sec007">
                <title>Study design</title>
                <p>This is a multicenter, cross-sectional analysis of prospectively collected subject data that was collected from spatially and temporally distinct cohorts. Cohort 1 included subjects from three geographically separate tertiary-care retina referral centers—the USC Roski Eye Institute (Los Angeles, CA), Retinal Consultants of Arizona (Phoenix, AZ) and Associated Retinal Consultants (Royal Oak, MI). Cohort 2 included subjects from a separate DR teleretinal screening center located at Los Angeles County + University of Southern California (LAC+USC) Medical Center (Los Angeles, CA). Approval was obtained from the University of Southern California Institutional Review Board (IRB) and Western IRB. The study adhered to the tenets of the Declaration of Helsinki. Subjects consented to have their data available for research purposes and this manuscript is based on secondary analyses of prospectively collected data.</p>
                <p>For Cohort 1, inclusion criteria for non-diabetic controls was availability of ophthalmological exam results and OCTA images at the time of clinical exam and no self-reported history of diabetes mellitus (DM). These were non-diabetic subjects where the examining ophthalmologist ruled out any significant ocular pathology. OCTA imaging is standard-of-care at these retina specialist clinics. Diabetic subjects were included if they had a known diagnosis of any DM, ophthalmological exam results which showed at least mild DR, and OCTA images at the time of clinical examination. Subject data was collected from February 2016 and June 2019.</p>
                <p>For Cohort 2, non-diabetic controls were not available because only diabetic subjects were referred for DR screening in the LAC+USC Teleretinal DR Screening clinic [<xref rid="pone.0262996.ref021" ref-type="bibr">21</xref>]. Subjects with diabetes were included in Cohort 2 if they had a conclusive DR diagnosis (with an official result in the teleretinal medical record) and simultaneous OCTA imaging. Data was collected between April and December 2019.</p>
                <p>Exclusion criteria for all subjects were use of any intraocular pressure lowering drops, any significant media opacity, and any other ophthalmic diagnosis except dry eye, vitreous syneresis, posterior vitreous detachment, asymptomatic epiretinal membrane without retinal distortion, peripheral retinal tear not requiring incisional surgery, and trauma without any notable sequelae.</p>
                <p>DR in subjects from Cohort 1 was classified based on a comprehensive ophthalmologic evaluation including dilated fundus examination performed by a board-certified and fellowship-trained retina specialist. DR categories were mild NPDR, moderate NPDR, severe NPDR and PDR based on the criteria set by the International Clinical DR and DME severity scales [<xref rid="pone.0262996.ref005" ref-type="bibr">5</xref>]. For subjects in Cohort 2, classification of DR was made using 3 nonmydriatic 45-degree digital fundus photographs which has significant agreement with 7-field ETDRS DR staging [<xref rid="pone.0262996.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0262996.ref023" ref-type="bibr">23</xref>]. DR staging was performed by an optometrist specifically trained and certified for teleretinal DR screening at the Los Angeles County screening clinic. This expert’s evaluation was then independently reviewed and adjudicated by one of our board certified and fellowship trained retina specialists. For all subjects, DME was assessed by manual review of all OCT B-scans. Demographic and clinical history including age, sex, and diagnoses of hyperlipidemia, hypertension, and diabetes were obtained from medical records in both cohorts.</p>
                <p>OCTA at all sites was performed using a commercially available CIRRUS AngioPlex 5000 (Carl Zeiss Meditec, Dublin, CA, USA). 3mm x 3mm images consisting of 245 horizontal B-scans and 245 individual A-scans per B-scan were obtained. OCTA images were included if they had a signal strength &gt; 7, were centered on the fovea, lacked significant hypo- or hyperreflective artifacts on <italic toggle="yes">en face</italic> structural images, and had fewer than 10 motion artifacts. If both eyes of a subject met the inclusion criteria, a highest quality image (fewest number of imaging artifacts) was determined as well.</p>
                <p>The superficial retinal layer (SRL) was the layer analyzed in all eyes to minimize the confounding impact of projection artifacts, projection artifact removal software, or layer segmentation. The commercially available Cirrus AngioPlex automated segmentation algorithm defined the SRL from the internal limiting membrane to the outer boundary of the inner plexiform layer. All OCT B-scan segmentation lines were reviewed for SRL segmentation errors and none of the images included in the final analysis required manual resegmentation.</p>
                <p>A previously validated, semi-automated, custom MATLAB (MathWorks Inc., Natlick, MA) algorithm was applied to a grayscale bitmap image of the SRL exported from the AngioPlex machine to calculate the VSD and VDI for each image [<xref rid="pone.0262996.ref006" ref-type="bibr">6</xref>–<xref rid="pone.0262996.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0262996.ref024" ref-type="bibr">24</xref>–<xref rid="pone.0262996.ref026" ref-type="bibr">26</xref>]. VSD is a measure of vascular length and is computed by skeletonizing all vessel segments to a width of one pixel, counting the number of pixels that represents all skeletonized vessels and dividing that by the total number of pixels in the image [<xref rid="pone.0262996.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0262996.ref015" ref-type="bibr">15</xref>]. VDI is derived by taking the number of pixels showing blood flow in a binarized OCTA image and dividing that by the number of pixels showing blood flow in a skeletonized OCTA image [<xref rid="pone.0262996.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0262996.ref015" ref-type="bibr">15</xref>].</p>
              </sec>
              <sec id="sec008">
                <title>Statistical analysis</title>
                <p>All statistical analysis and regression models were performed using SAS Version 9.4 (Cary, North Carolina). A post-hoc analysis of study power was performed. We found that our sample size provides more than 80% power for detecting significant differences between the control and any DR groups and the mild DR and referable DR groups for VSD or VDI.</p>
                <p>A mixed effects multinomial logistic regression model was developed using subjects from Cohort 1 as the training cohort and modeling disease severity as the dependent nominal variable with 3 levels including control, mild, and referable DR (a previously defined group [<xref rid="pone.0262996.ref027" ref-type="bibr">27</xref>] which included moderate/severe NPDR, and PDR). Routinely collected clinical and demographic data shown to be potential predictors of DR were considered for model inclusion with VSD and VDI: these included age, sex, hypertension, and hyperlipidemia. Variables significantly associated with the DR severity outcome in a univariable model were selected for a multivariable model using a backward and stepwise elimination method until a parsimonious model with all variables statistically significant at p &lt; 0.05 via the Satterthwaite denominator degree-of-freedom method was obtained. During this process, age was removed from the model, so that the complete model included VSD, VDI, sex, hypertension, and hyperlipidemia. In other words, age was not a significant confounder for our models and thus age was not retained as a covariate. Other work has previously failed to find an association between age and severity of retinopathy [<xref rid="pone.0262996.ref028" ref-type="bibr">28</xref>]. All models were adjusted for the random effects of eye-nesting within subject and ophthalmic center. The Newton-Raphson with ridging optimization technique was utilized to help with the convergence of the procedures. All models we subsequently describe show acceptable goodness-of-fit with the Hosmer-Lemeshow test p &gt; 0.05, indicating our models are well-calibrated.</p>
                <p>The discriminatory performance of the final multivariable model in determining any DR versus controls and referable DR versus mild DR was assessed by generating receiver operating characteristic (ROC) curves and calculating the area under the curve (AUC).</p>
                <p>For each classification of interest, the AUC from models including VSD, VDI, or both VSD and VDI was compared nonparametrically to a general covariate model called “Model 1” that included only sex, hypertension, and hyperlipidemia in order to determine the incremental discriminatory contribution of OCTA metrics [<xref rid="pone.0262996.ref029" ref-type="bibr">29</xref>]. The p-value for the null hypothesis that the difference in the AUCs = 0 was generated by estimating a covariance matrix using the method of structural components and computing the test statistic having an asymptotically chi-square distribution [<xref rid="pone.0262996.ref029" ref-type="bibr">29</xref>].</p>
                <p>Each constrained comparison of interest was further internally validated for the complete prediction model using ten-fold cross validation. This involved splitting the data into ten equally sized groups, estimating the model coefficients on 9 of the 10 groups, and then evaluating its accuracy in the group held out. The AUC was averaged over the 10 validation sets and reported as the evaluation metric. The prediction model derived from Cohort 1 was then applied to data from Cohort 2 which served as a validation data set. Model performance for the referable DR versus mild DR comparison in Cohort 2 was similarly quantified by calculating the AUC; incremental contributions of VSD and VDI were assessed as described for Cohort 1.</p>
                <p>Using one highest quality single image for each subject in both cohorts, ROC-based thresholds were used to estimate the optimal values for both VSD and VDI in discriminating any DR versus control and referable DR versus mild DR. The threshold giving the highest correct classification rate was chosen as the most appropriate summary measure.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec009">
              <title>Results</title>
              <p>A total of 594 eyes (385 subjects) were included in both cohorts (<xref rid="pone.0262996.t001" ref-type="table">Table 1</xref>). In Cohort 1, all subject characteristics (age, sex, hyperlipidemia, hypertension, and DME) were found to differ significantly between groups and were considered potential predictors of DR, except for DME because it perfectly predicted DR.</p>
              <table-wrap position="float" id="pone.0262996.t001">
                <object-id pub-id-type="doi">10.1371/journal.pone.0262996.t001</object-id>
                <label>Table 1</label>
                <caption>
                  <title>Demographics.</title>
                </caption>
                <alternatives>
                  <graphic xlink:href="pone.0262996.t001" id="pone.0262996.t001g" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="justify" rowspan="2" colspan="1"/>
                        <th align="center" colspan="3" rowspan="1">DR Severity in Cohort 1</th>
                        <th align="center" rowspan="2" colspan="1">p-value</th>
                        <th align="center" colspan="2" rowspan="1">DR Severity in Cohort 2</th>
                        <th align="center" rowspan="2" colspan="1">p-value</th>
                      </tr>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">
                          <underline>Control</underline>
                        </th>
                        <th align="center" rowspan="1" colspan="1">
                          <underline>Mild</underline>
                        </th>
                        <th align="center" rowspan="1" colspan="1">
                          <underline>Referable</underline>
                        </th>
                        <th align="center" rowspan="1" colspan="1">
                          <underline>Mild</underline>
                        </th>
                        <th align="center" rowspan="1" colspan="1">
                          <underline>Referable</underline>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">N eyes</td>
                        <td align="center" rowspan="1" colspan="1">159</td>
                        <td align="center" rowspan="1" colspan="1">155</td>
                        <td align="center" rowspan="1" colspan="1">195</td>
                        <td align="center" rowspan="1" colspan="1">-</td>
                        <td align="center" rowspan="1" colspan="1">16</td>
                        <td align="center" rowspan="1" colspan="1">69</td>
                        <td align="center" rowspan="1" colspan="1">-</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">N subjects <xref rid="t001fn003" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td align="center" rowspan="1" colspan="1">102</td>
                        <td align="center" rowspan="1" colspan="1">100</td>
                        <td align="center" rowspan="1" colspan="1">129</td>
                        <td align="center" rowspan="1" colspan="1">-</td>
                        <td align="center" rowspan="1" colspan="1">12</td>
                        <td align="center" rowspan="1" colspan="1">42</td>
                        <td align="center" rowspan="1" colspan="1">-</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"><bold>Characteristics of subjects</bold>:</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Mean Age, years (SD)</td>
                        <td align="center" rowspan="1" colspan="1">51.0 (17.9)</td>
                        <td align="center" rowspan="1" colspan="1">57.3 (13.4)</td>
                        <td align="center" rowspan="1" colspan="1">57.3 (12.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.002 <xref rid="t001fn002" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td align="center" rowspan="1" colspan="1">50.5 (15.0)</td>
                        <td align="center" rowspan="1" colspan="1">54.0 (10.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">.35 <xref rid="t001fn002" ref-type="table-fn"><sup>b</sup></xref></td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age range, years</td>
                        <td align="center" rowspan="1" colspan="1">21–86</td>
                        <td align="center" rowspan="1" colspan="1">23–80</td>
                        <td align="center" rowspan="1" colspan="1">29–91</td>
                        <td align="center" rowspan="1" colspan="1">-</td>
                        <td align="center" rowspan="1" colspan="1">28–68</td>
                        <td align="center" rowspan="1" colspan="1">23–86</td>
                        <td align="center" rowspan="1" colspan="1">-</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Female sex, No. (%)</td>
                        <td align="center" rowspan="1" colspan="1">61 (59.8%)</td>
                        <td align="center" rowspan="1" colspan="1">42 (42.0%)</td>
                        <td align="center" rowspan="1" colspan="1">63 (48.8%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.04 <xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="center" rowspan="1" colspan="1">6 (50.0%)</td>
                        <td align="center" rowspan="1" colspan="1">17 (40.5%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.74 <xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hyperlipidemia, No. (%)</td>
                        <td align="center" rowspan="1" colspan="1">9 (8.8%)</td>
                        <td align="center" rowspan="1" colspan="1">37 (37.0%)</td>
                        <td align="center" rowspan="1" colspan="1">58 (45.0%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.001 <xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="center" rowspan="1" colspan="1">5 (41.7%)</td>
                        <td align="center" rowspan="1" colspan="1">18 (42.9%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">1.00 <xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypertension, No. (%)</td>
                        <td align="center" rowspan="1" colspan="1">18 (17.6%)</td>
                        <td align="center" rowspan="1" colspan="1">53 (53.0%)</td>
                        <td align="center" rowspan="1" colspan="1">91 (70.5%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.001 <xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="center" rowspan="1" colspan="1">7 (58.3%)</td>
                        <td align="center" rowspan="1" colspan="1">26 (61.9%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">1.00 <xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">DME, No. (%)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0.0%)</td>
                        <td align="center" rowspan="1" colspan="1">9 (9.0%)</td>
                        <td align="center" rowspan="1" colspan="1">65 (50.4%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.001 <xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="center" rowspan="1" colspan="1">2 (16.7%)</td>
                        <td align="center" rowspan="1" colspan="1">18 (42.9%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.17 <xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t001fn001">
                    <p><sup>a</sup>Chi-squared test or Fisher’s exact test, as appropriate.</p>
                  </fn>
                  <fn id="t001fn002">
                    <p><sup>b</sup>One-way analysis of variance.</p>
                  </fn>
                  <fn id="t001fn003">
                    <p><sup>c</sup>Subjects with eyes of varying DR severity were counted as part of their least severely diseased eye.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The VSD and VDI were computed for each subject and the distribution of the data in Cohort 1 is shown in <xref rid="pone.0262996.g001" ref-type="fig">Fig 1</xref>. The VSD, mean [SD], for the control group, mild DR group and referable DR group in Cohort 1 was 0.153 [0.006], 0.146 [0.010], and 0.131 [0.012], respectively, while the VDI for each of these groups was 2.90 [0.05], 2.92 [0.08], and 3.01 [0.11], respectively. In Cohort 2, the VSD, mean [SD], for the mild and referable DR categories was 0.149 [0.007] and 0.135 [0.014], respectively, while the VDI for each of these groups was 2.93 [0.06] and 3.00 [0.09], respectively.</p>
              <fig position="float" id="pone.0262996.g001">
                <object-id pub-id-type="doi">10.1371/journal.pone.0262996.g001</object-id>
                <label>Fig 1</label>
                <caption>
                  <title>Box and whisker plots of the VSD and VDI distribution in the tertiary referral centers (Cohort 1).</title>
                  <p>Start and end of boxes represent 25<sup>th</sup> and 75<sup>th</sup> quartiles respectively. Vertical lines extend to the smallest and largest values no further than 1.5 times the interquartile range. The middle horizontal line represents the median and the black square box represents the mean. Outliers are plotted as circles.</p>
                </caption>
                <graphic xlink:href="pone.0262996.g001" position="float"/>
              </fig>
              <p>The odds ratios for changes in individual components on which the complete multivariate model was built are shown in <xref rid="pone.0262996.t002" ref-type="table">Table 2</xref>. After refitting the model to produce constrained comparisons of interest, the odds ratio of having any DR compared to control subjects and referable DR compared to mild DR decreased by 15% (95% CI: 12–18%), and 13% (95% CI: 10–15%), respectively for every 0.001 unit increase in VSD. The odds of having any DR compared to control subjects and referable DR compared to mild DR increased by 10% (95% CI: 7–13%) in both cases for every 0.01 unit increase in VDI.</p>
              <table-wrap position="float" id="pone.0262996.t002">
                <object-id pub-id-type="doi">10.1371/journal.pone.0262996.t002</object-id>
                <label>Table 2</label>
                <caption>
                  <title>Complete multivariable model odds ratios.</title>
                </caption>
                <alternatives>
                  <graphic xlink:href="pone.0262996.t002" id="pone.0262996.t002g" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="justify" rowspan="2" colspan="1">Predictor</th>
                        <th align="center" colspan="2" rowspan="1">OR (95% CI)</th>
                        <th align="center" rowspan="1" colspan="1">p-value</th>
                      </tr>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">Mild versus Control</th>
                        <th align="center" rowspan="1" colspan="1">Referable versus Control</th>
                        <th align="center" rowspan="1" colspan="1"/>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="justify" rowspan="1" colspan="1">
                          <bold>VSD</bold>
                          <xref rid="t002fn001" ref-type="table-fn">
                            <sup>1</sup>
                          </xref>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.89 (0.85, 0.93)</td>
                        <td align="center" rowspan="1" colspan="1">0.78 (0.74, 0.82)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="justify" rowspan="1" colspan="1">
                          <bold>VDI</bold>
                          <xref rid="t002fn001" ref-type="table-fn">
                            <sup>1</sup>
                          </xref>
                        </td>
                        <td align="center" rowspan="1" colspan="1">1.05 (1.01,1.09)</td>
                        <td align="center" rowspan="1" colspan="1">1.13 (1.08,1.18)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="justify" rowspan="1" colspan="1">
                          <bold>Male</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">2.63 (1.52, 4.55)</td>
                        <td align="center" rowspan="1" colspan="1">1.32 (0.66, 2.63)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="justify" rowspan="1" colspan="1">
                          <bold>Hyperlipidemia</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">3.54 (1.61,7.80)</td>
                        <td align="center" rowspan="1" colspan="1">2.40 (0.96,5.99)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.006</td>
                      </tr>
                      <tr>
                        <td align="justify" rowspan="1" colspan="1">
                          <bold>Hypertension</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">3.29 (1.76,6.18)</td>
                        <td align="center" rowspan="1" colspan="1">5.81 (2.69,12.54)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t002fn001">
                    <p><sup>1</sup>ORs and their 95% CIs are reported per 0.001 unit increase in VSD and 0.01 unit increase in VDI.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="sec010">
                <title>Multivariate model performance in discriminating between any DR severity versus control and referable DR versus mild NPDR</title>
                <p><xref rid="pone.0262996.g002" ref-type="fig">Fig 2</xref> shows the ROC curves for classifications of any DR versus control and referable DR versus mild DR in Cohort 1. The AUCs for Model 1 classifying any DR versus control and referable DR versus mild DR as seen in <xref rid="pone.0262996.t003" ref-type="table">Table 3</xref> were 0.80 (95% CI: 0.76–0.84) and 0.69 (95% CI: 0.64–0.75), respectively. The addition of VSD significantly (p &lt; 0.001) increased Model 1’s AUC by 0.10 to 0.90 (95% CI: 0.87–0.93) and by 0.19 to 0.88 (95% CI: 0.84–0.91) for any DR versus control and referable DR versus mild DR, respectively. The addition of VDI to Model 1 increased the AUC by 0.05 to 0.85 (95% CI: 0.82–0.88) and by 0.12 to 0.81 (95% CI: 0.76–0.86) respectively, for any DR versus control and referable DR versus mild DR. A comprehensive model with VSD, VDI, sex, hypertension, and hyperlipidemia was significantly (p ≤ 0.02 for every case) superior in its discriminatory ability compared to any other combination of comorbid factors with VSD or VDI, with an AUC of 0.91 (95% CI: 0.88–0.93) and 0.90 (95% CI: 0.86–0.93) for any DR versus control and referable DR versus mild DR, respectively. Model AUCs along with sensitivity and specificity are shown in <xref rid="pone.0262996.t003" ref-type="table">Table 3</xref>.</p>
                <fig position="float" id="pone.0262996.g002">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0262996.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Receiver operator characteristic (ROC) curves.</title>
                    <p>ROC curves for the constrained comparisons of any DR severity versus control and referable DR versus mild non-proliferative DR in Cohort 1. Additional lines are drawn for the sequential addition of VSD and VDI as parameters to the baseline model (labeled Model 1 and drawn in blue) containing sex, hypertension, and hyperlipidemia. A red line is drawn for a model with the parameters for Model 1 with VSD (red), a green line is drawn for a model with the parameters of Model 1 with VDI (green), and a brown line is drawn for the complete model containing the parameters of Model 1 with VSD and VDI (brown). Area under the curve for each ROC curve is listed in parenthesis next to each model in the legend.</p>
                  </caption>
                  <graphic xlink:href="pone.0262996.g002" position="float"/>
                </fig>
                <table-wrap position="float" id="pone.0262996.t003">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0262996.t003</object-id>
                  <label>Table 3</label>
                  <caption>
                    <title>Model evaluation.</title>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="pone.0262996.t003" id="pone.0262996.t003g" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">DR Comparison</th>
                          <th align="center" rowspan="1" colspan="1">Model</th>
                          <th align="center" rowspan="1" colspan="1">Internal Validation AUC (95% CI)</th>
                          <th align="center" rowspan="1" colspan="1">AUC (95% CI)</th>
                          <th align="center" rowspan="1" colspan="1">p-value</th>
                          <th align="center" rowspan="1" colspan="1">Sensitivity (95% CI)</th>
                          <th align="center" rowspan="1" colspan="1">Specificity (95% CI)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="justify" colspan="5" rowspan="1">
                            <bold>Performance of Cohort 1 Model</bold>
                          </td>
                          <td align="justify" rowspan="1" colspan="1"/>
                          <td align="justify" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="justify" rowspan="2" colspan="1">
                            <italic toggle="yes">Any DR severity (mild and referable DR) versus Control</italic>
                          </td>
                          <td align="justify" rowspan="1" colspan="1">Model 1<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref> + VSD + VDI</td>
                          <td align="center" rowspan="2" colspan="1">0.90 (0.87–0.93)</td>
                          <td align="center" rowspan="1" colspan="1">0.91 (0.88–0.93)</td>
                          <td align="char" char="." rowspan="2" colspan="1">&lt;0.001 <xref rid="t003fn002" ref-type="table-fn"><sup>b</sup></xref></td>
                          <td align="center" rowspan="2" colspan="1">0.89 (0.85–0.92)</td>
                          <td align="center" rowspan="2" colspan="1">0.69 (0.61–0.76)</td>
                        </tr>
                        <tr>
                          <td align="justify" rowspan="1" colspan="1">Model 1<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">0.80 (0.76–0.84)</td>
                        </tr>
                        <tr>
                          <td align="justify" rowspan="2" colspan="1">
                            <italic toggle="yes">Referable DR versus Mild DR</italic>
                          </td>
                          <td align="justify" rowspan="1" colspan="1">Model 1<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref> + VSD + VDI</td>
                          <td align="center" rowspan="2" colspan="1">0.87 (0.83–0.91)</td>
                          <td align="center" rowspan="1" colspan="1">0.90 (0.86–0.93)</td>
                          <td align="char" char="." rowspan="2" colspan="1">&lt;0.001 <xref rid="t003fn002" ref-type="table-fn"><sup>b</sup></xref></td>
                          <td align="center" rowspan="2" colspan="1">0.89 (0.83–0.93)</td>
                          <td align="center" rowspan="2" colspan="1">0.66 (0.58–0.73)</td>
                        </tr>
                        <tr>
                          <td align="justify" rowspan="1" colspan="1">Model 1<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">0.69 (0.64–0.75)</td>
                        </tr>
                        <tr>
                          <td align="justify" colspan="5" rowspan="1">
                            <bold>Performance of Cohort 1 Model Applied to Cohort 2</bold>
                          </td>
                          <td align="justify" rowspan="1" colspan="1"/>
                          <td align="justify" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="justify" rowspan="2" colspan="1">
                            <italic toggle="yes">Referable DR versus Mild DR</italic>
                          </td>
                          <td align="justify" rowspan="1" colspan="1">Model 1<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref> + VSD + VDI</td>
                          <td align="center" rowspan="2" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.82 (0.70-.93)</td>
                          <td align="char" char="." rowspan="2" colspan="1">&lt;0.001 <xref rid="t003fn002" ref-type="table-fn"><sup>b</sup></xref></td>
                          <td align="center" rowspan="2" colspan="1">0.75</td>
                          <td align="center" rowspan="2" colspan="1">0.68</td>
                        </tr>
                        <tr>
                          <td align="justify" rowspan="1" colspan="1">Model 1<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">0.46 (0.32-.61)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t003fn001">
                      <p><sup>a</sup>Model 1 represents the multivariate model consisting of the subject’s sex, hypertensive status, and hyperlipidemia status.</p>
                    </fn>
                    <fn id="t003fn002">
                      <p><sup>b</sup>p-value for ROC contrast with Model 1.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <sec id="sec011">
                  <title>Internal validation</title>
                  <p>For the complete model predicting any DR versus control and referable DR versus mild DR from Cohort 1, internal validation from the 10-fold cross validation reinforced strong discriminatory ability, with a mean AUC across all repetitions of cross-validation of 0.90 (95%: 0.87–0.93) and 0.87 (95%: 0.83–0.91) respectively.</p>
                </sec>
                <sec id="sec012">
                  <title>External validation</title>
                  <p><xref rid="pone.0262996.t003" ref-type="table">Table 3</xref> also summarizes the results of the external validation and transportability of the model developed in Cohort 1 when applied to data from Cohort 2. Notably, VSD and VDI each individually significantly contribute to the predictive performance of the model in Cohort 2 as they did in Cohort 1. Compared to the Model 1 AUC of 0.46 (95% CI: 0.32–0.61) in this population, VSD increased the model AUC by 0.35 to 0.81 (95% CI: 0.69–0.93) and VDI increased the model AUC by 0.22 to 0.68 (95% CI: 0.54–0.82) in Cohort 2. The complete model with VSD and VDI was significantly better at discriminating referable DR from mild DR subjects (AUC: 0.82, 95% CI: 0.70–0.93) than Model 1 although it was not significantly different than Model 1 with VSD (p = 0.79).</p>
                </sec>
                <sec id="sec013">
                  <title>Optimal VSD and VDI cutoff points</title>
                  <p>After combining both cohorts, a VSD cutoff of 0.153 (correct classification rate of 0.84) and 0.143 (correct classification rate of 0.79) best discriminated subjects with any DR from control and subjects with referable DR from mild DR, respectively. Similarly, the VDI cut points were 2.91 (correct classification rate of 0.82) and 2.97 (correct classification rate of 0.72) for the same comparisons, respectively.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec014">
              <title>Discussion</title>
              <p>Clinical classification of DR is a critical step in the management of DR but it is also a laborious process for patients and physicians. Clinically feasible screening methods can play an important role in improving DR classification and clinical care. This is particularly true in the early stages of DR when ophthalmoscopic findings are subtle and clinical examination is therefore of low yield. In this study, we demonstrate that vessel skeleton density (VSD) significantly improves discrimination of clinically important DR categories in comparison to age, sex, and medical comorbidities alone among a population of subjects evaluated for DR by a retina specialist. In addition, the same finding holds true when VSD is applied in a cohort of patients referred for evaluation of DR via a teleretinal screening clinic using fundus photography. These findings suggest that OCTA-derived metrics can significantly improve or complement staging of DR in real-world clinical settings.</p>
              <p>This additional discriminatory ability beyond demographic factors is likely due to the near histologic resolution of OCTA [<xref rid="pone.0262996.ref030" ref-type="bibr">30</xref>] that allows unprecedented detection of flow impairment. As our models show, this provides a significant advantage that can be leveraged in the clinical setting to improve disease classification even without knowledge about the funduscopic appearance of the retina or invasive laboratory tests such as HgA1c. Moreover, the earliest signs of DR, such as dot-and-blot hemorrhages and microaneurysms, can appear and disappear over time thereby eluding ophthalmoscopic detection. Even when present, these lesions can be subtle and difficult to detect reliably in a busy clinical setting. In contrast, OCTA-derived measures of capillary density provide an optical biopsy of retinal capillary perfusion that reflects the accumulating capillary pathology from DM rather than the transient ophthalmoscopic findings characteristic of early DR [<xref rid="pone.0262996.ref031" ref-type="bibr">31</xref>].</p>
              <p>Our analysis was performed on subject data generated by 9 board certified and fellowship-trained retina specialists located in three geographically separate tertiary care retina referral centers. Therefore, we believe that the data used in our modeling represents a reasonable sample of clinical DR classification as it occurs in the United States. Ten-fold internal cross-validation of our results further confirmed our findings. The training data of Cohort 1 was derived from subjects that come from relatively affluent and insured patient populations. In order to demonstrate that our model is applicable in other settings, we used it to categorize images from a cohort of primarily Latino, low-income, and under-insured patients from a teleretinal DR screening clinic in Los Angeles County, Cohort 2. The test cohort in this case was created to validate the conclusions of Cohort 1 in a rigorous way by taking advantage of the multicenter nature of this study [<xref rid="pone.0262996.ref032" ref-type="bibr">32</xref>]. The significant incremental improvement in discriminating referable DR from mild DR in this validation cohort demonstrates the robust and reliable nature of OCTA-derived capillary density. Perhaps the most important finding of this study was the validation of the complete model generated from Cohort 1 in the external validation cohort in the most clinically relevant comparison of referable DR versus mild DR.</p>
              <p>OCTA-derived capillary density appears to be particularly sensitive to DR with a decrease in the odds of any DR versus control and referable DR versus mild DR ranging from 13–15% for every 0.001 increase in VSD. Since VSD values typically decrease in subjects with increasing severity of DR it can be more intuitive to consider the inverse [<xref rid="pone.0262996.ref007" ref-type="bibr">7</xref>]. For every 0.001 unit decrease in VSD, the odds of having any DR compared to control subjects and referable DR compared to mild DR increases by 18% (95% CI: 14–22%) and 15% (95% CI: 11–18%), respectively. The range of capillary density in the Cohort 1 dataset spanned VSD values of 0.076 to 0.167. This is orders of magnitude larger than the incrementally significant change in VSD of 0.001 which means that large VSD changes suggest dramatically increased risk. Our analysis also suggests the addition of other OCTA-derived metrics (e.g. VDI) may be useful as well [<xref rid="pone.0262996.ref033" ref-type="bibr">33</xref>]. In the future, the accuracy of the categorization of DR may be further increased by using techniques such as image averaging [<xref rid="pone.0262996.ref034" ref-type="bibr">34</xref>].</p>
              <sec id="sec015">
                <title>Limitations</title>
                <p>One possible limitation of this study is that we did not analyze the deep retinal layer (DRL) though this decision was made for several reasons [<xref rid="pone.0262996.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0262996.ref035" ref-type="bibr">35</xref>–<xref rid="pone.0262996.ref038" ref-type="bibr">38</xref>]. Durbin et al. have reported that the AUC of retinal capillary density in the SRL was the best for detecting DR [<xref rid="pone.0262996.ref011" ref-type="bibr">11</xref>]. SRL vessel density changes may also be more reliably detectable than those in the DRL [<xref rid="pone.0262996.ref039" ref-type="bibr">39</xref>–<xref rid="pone.0262996.ref041" ref-type="bibr">41</xref>]. SRL analysis also does not require projection artifact removal which is available but not clearly validated against a meaningful ground truth [<xref rid="pone.0262996.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0262996.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0262996.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0262996.ref043" ref-type="bibr">43</xref>]. Reproducibility and repeatability has been shown in the SRL [<xref rid="pone.0262996.ref044" ref-type="bibr">44</xref>] as well. Though axial length calibration may also affect the VSD and VDI measurements [<xref rid="pone.0262996.ref045" ref-type="bibr">45</xref>], this information is not readily available at a diabetic retinopathy screening center which comprised our validation cohort.</p>
                <p>The nature of this study as a secondary analysis created additional limitations. This prevents us from claiming that this is a predictive model as patients were not prospectively categorized before classification by the ophthalmologist. Furthermore, the model does not incorporate certain patient demographics including those with diabetes without DR, and thus the any DR versus control comparison could not be validated in our external cohort. All of these concerns could be further addressed by a prospective study.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec016">
              <title>Conclusions</title>
              <p>VSD and VDI calculated from OCTA images of the SRL provide additional information in discriminating between subjects with DR and healthy individuals and between subjects with referable DR and mild DR beyond that of common medical historical covariates: age, sex, hyperlipidemia, and hypertension. Our model’s high performance in differentiating referable DR from mild DR was transportable from a tertiary care cohort to a teleretinal screening cohort. In each of these cases, VSD showed more robustness across these comparisons than VDI in the DR subject population.</p>
            </sec>
          </body>
          <back>
            <ref-list>
              <title>References</title>
              <ref id="pone.0262996.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>R</given-names></name>, <name><surname>Wong</surname><given-names>TY</given-names></name>, <name><surname>Sabanayagam</surname><given-names>C</given-names></name>. <article-title>Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss</article-title>. <source>Eye and Vis</source>. <year>2015</year>;<volume>2</volume>: <fpage>17</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s40662-015-0026-2</pub-id><?supplied-pmid 26605370?><pub-id pub-id-type="pmid">26605370</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>TY</given-names></name>, <name><surname>Liew</surname><given-names>G</given-names></name>, <name><surname>Tapp</surname><given-names>RJ</given-names></name>, <name><surname>Schmidt</surname><given-names>MI</given-names></name>, <name><surname>Wang</surname><given-names>JJ</given-names></name>, <name><surname>Mitchell</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies</article-title>. <source>The Lancet</source>. <year>2008</year>;<volume>371</volume>: <fpage>736</fpage>–<lpage>743</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60343-8</pub-id>
<?supplied-pmid 18313502?><pub-id pub-id-type="pmid">18313502</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Lo</surname><given-names>A</given-names></name>. <article-title>Diabetic Retinopathy: Pathophysiology and Treatments</article-title>. <source>IJMS</source>. <year>2018</year>;<volume>19</volume>: <fpage>1816</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms19061816</pub-id><?supplied-pmid 29925789?><pub-id pub-id-type="pmid">29925789</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><article-title>Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs—An Extension of the Modified Airlie House Classification</article-title>. <source>Ophthalmology</source>. <year>1991</year>;<volume>98</volume>: <fpage>786</fpage>–<lpage>806</lpage>.<pub-id pub-id-type="pmid">2062513</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Wilkinson</surname><given-names>CP</given-names></name>, <name><surname>Ferris</surname><given-names>FL</given-names></name>, <name><surname>Klein</surname><given-names>RE</given-names></name>, <name><surname>Lee</surname><given-names>PP</given-names></name>, <name><surname>Agardh</surname><given-names>CD</given-names></name>, <name><surname>Davis</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales</article-title>. <source>Ophthalmology</source>. <year>2003</year>;<volume>110</volume>: <fpage>1677</fpage>–<lpage>1682</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0161-6420(03)00475-5</pub-id>
<?supplied-pmid 13129861?><pub-id pub-id-type="pmid">13129861</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Koulisis</surname><given-names>N</given-names></name>, <name><surname>Kim</surname><given-names>AY</given-names></name>, <name><surname>Chu</surname><given-names>Z</given-names></name>, <name><surname>Shahidzadeh</surname><given-names>A</given-names></name>, <name><surname>Burkemper</surname><given-names>B</given-names></name>, <name><surname>Olmos de Koo</surname><given-names>LC</given-names></name>, <etal>et al</etal>. <article-title>Quantitative microvascular analysis of retinal venous occlusions by spectral domain optical coherence tomography angiography</article-title>. <name><surname>Vavvas</surname><given-names>DG</given-names></name>, editor. <source>PLoS ONE</source>. <year>2017</year>;<volume>12</volume>: <fpage>e0176404</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0176404</pub-id><?supplied-pmid 28437483?><pub-id pub-id-type="pmid">28437483</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>AY</given-names></name>, <name><surname>Chu</surname><given-names>Z</given-names></name>, <name><surname>Shahidzadeh</surname><given-names>A</given-names></name>, <name><surname>Wang</surname><given-names>RK</given-names></name>, <name><surname>Puliafito</surname><given-names>CA</given-names></name>, <name><surname>Kashani</surname><given-names>AH</given-names></name>. <article-title>Quantifying Microvascular Density and Morphology in Diabetic Retinopathy Using Spectral-Domain Optical Coherence Tomography Angiography</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2016</year>;<volume>57</volume>: <fpage>OCT362</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1167/iovs.15-18904</pub-id><?supplied-pmid 27409494?><pub-id pub-id-type="pmid">27409494</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>AY</given-names></name>, <name><surname>Rodger</surname><given-names>DC</given-names></name>, <name><surname>Shahidzadeh</surname><given-names>A</given-names></name>, <name><surname>Chu</surname><given-names>Z</given-names></name>, <name><surname>Koulisis</surname><given-names>N</given-names></name>, <name><surname>Burkemper</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Quantifying Retinal Microvascular Changes in Uveitis Using Spectral-Domain Optical Coherence Tomography Angiography</article-title>. <source>American Journal of Ophthalmology</source>. <year>2016</year>;<volume>171</volume>: <fpage>101</fpage>–<lpage>112</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2016.08.035</pub-id>
<?supplied-pmid 27594138?><pub-id pub-id-type="pmid">27594138</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Nesper</surname><given-names>PL</given-names></name>, <name><surname>Soetikno</surname><given-names>BT</given-names></name>, <name><surname>Zhang</surname><given-names>HF</given-names></name>, <name><surname>Fawzi</surname><given-names>AA</given-names></name>. <article-title>OCT angiography and visible-light OCT in diabetic retinopathy</article-title>. <source>Vision Research</source>. <year>2017</year>;<volume>139</volume>: <fpage>191</fpage>–<lpage>203</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.visres.2017.05.006</pub-id>
<?supplied-pmid 28601429?><pub-id pub-id-type="pmid">28601429</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Zahid</surname><given-names>S</given-names></name>, <name><surname>Dolz-Marco</surname><given-names>R</given-names></name>, <name><surname>Freund</surname><given-names>KB</given-names></name>, <name><surname>Balaratnasingam</surname><given-names>C</given-names></name>, <name><surname>Dansingani</surname><given-names>K</given-names></name>, <name><surname>Gilani</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Fractal Dimensional Analysis of Optical Coherence Tomography Angiography in Eyes With Diabetic Retinopathy</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2016</year>;<volume>57</volume>: <fpage>4940</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1167/iovs.16-19656</pub-id><?supplied-pmid 27654421?><pub-id pub-id-type="pmid">27654421</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Durbin</surname><given-names>MK</given-names></name>, <name><surname>An</surname><given-names>L</given-names></name>, <name><surname>Shemonski</surname><given-names>ND</given-names></name>, <name><surname>Soares</surname><given-names>M</given-names></name>, <name><surname>Santos</surname><given-names>T</given-names></name>, <name><surname>Lopes</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Quantification of Retinal Microvascular Density in Optical Coherence Tomographic Angiography Images in Diabetic Retinopathy</article-title>. <source>JAMA Ophthalmol</source>. <year>2017</year>;<volume>135</volume>: <fpage>370</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2017.0080</pub-id><?supplied-pmid 28301651?><pub-id pub-id-type="pmid">28301651</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Hwang</surname><given-names>TS</given-names></name>, <name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Bhavsar</surname><given-names>K</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Campbell</surname><given-names>JP</given-names></name>, <name><surname>Lin</surname><given-names>P</given-names></name>, <etal>et al</etal>. <source>Visualization of 3 Distinct Retinal Plexuses by Projection-Resolved Optical Coherence Tomography Angiography in Diabetic Retinopathy</source>. <year>2016</year>; <volume>9</volume>.</mixed-citation>
              </ref>
              <ref id="pone.0262996.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Ting</surname><given-names>DSW</given-names></name>, <name><surname>Tan</surname><given-names>GSW</given-names></name>, <name><surname>Agrawal</surname><given-names>R</given-names></name>, <name><surname>Yanagi</surname><given-names>Y</given-names></name>, <name><surname>Sie</surname><given-names>NM</given-names></name>, <name><surname>Wong</surname><given-names>CW</given-names></name>, <etal>et al</etal>. <article-title>Optical Coherence Tomographic Angiography in Type 2 Diabetes and Diabetic Retinopathy</article-title>. <source>JAMA Ophthalmol</source>. <year>2017</year>;<volume>135</volume>: <fpage>306</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2016.5877</pub-id><?supplied-pmid 28208170?><pub-id pub-id-type="pmid">28208170</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Kashani</surname><given-names>AH</given-names></name>, <name><surname>Chen</surname><given-names>C-L</given-names></name>, <name><surname>Gahm</surname><given-names>JK</given-names></name>, <name><surname>Zheng</surname><given-names>F</given-names></name>, <name><surname>Richter</surname><given-names>GM</given-names></name>, <name><surname>Rosenfeld</surname><given-names>PJ</given-names></name>, <etal>et al</etal>. <article-title>Optical coherence tomography angiography: A comprehensive review of current methods and clinical applications</article-title>. <source>Progress in Retinal and Eye Research</source>. <year>2017</year>;<volume>60</volume>: <fpage>66</fpage>–<lpage>100</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.preteyeres.2017.07.002</pub-id>
<?supplied-pmid 28760677?><pub-id pub-id-type="pmid">28760677</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Reif</surname><given-names>R</given-names></name>, <name><surname>Qin</surname><given-names>J</given-names></name>, <name><surname>An</surname><given-names>L</given-names></name>, <name><surname>Zhi</surname><given-names>Z</given-names></name>, <name><surname>Dziennis</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>R</given-names></name>. <article-title>Quantifying Optical Microangiography Images Obtained from a Spectral Domain Optical Coherence Tomography System</article-title>. <source>International Journal of Biomedical Imaging</source>. <year>2012</year>;<volume>2012</volume>: <fpage>1</fpage>–<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2012/509783</pub-id>
<?supplied-pmid 22792084?><pub-id pub-id-type="pmid">22792084</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Kushner-Lenhoff</surname><given-names>S</given-names></name>, <name><surname>Ashimatey</surname><given-names>BS</given-names></name>, <name><surname>Kashani</surname><given-names>AH</given-names></name>. <article-title>Retinal Vascular Reactivity as Assessed by Optical Coherence Tomography Angiography</article-title>. <source>JoVE</source>. <year>2020</year>; <fpage>e60948</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3791/60948</pub-id><?supplied-pmid 32281974?><pub-id pub-id-type="pmid">32281974</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Agemy</surname><given-names>SA</given-names></name>, <name><surname>Scripsema</surname><given-names>NK</given-names></name>, <name><surname>Shah</surname><given-names>CM</given-names></name>, <name><surname>Chui</surname><given-names>T</given-names></name>, <name><surname>Garcia</surname><given-names>PM</given-names></name>, <name><surname>Lee</surname><given-names>JG</given-names></name>, <etal>et al</etal>. <article-title>RETINAL VASCULAR PERFUSION DENSITY MAPPING USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NORMALS AND DIABETIC RETINOPATHY PATIENTS</article-title>: <source>Retina</source>. <year>2015</year>;<volume>35</volume>: <fpage>2353</fpage>–<lpage>2363</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/IAE.0000000000000862</pub-id>
<?supplied-pmid 26465617?><pub-id pub-id-type="pmid">26465617</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Cheung</surname><given-names>CMG</given-names></name>, <name><surname>Wong</surname><given-names>TY</given-names></name>. <article-title>Clinical Use of Optical Coherence Tomography Angiography in Diabetic Retinopathy Treatment: Ready for Showtime?</article-title><source>JAMA Ophthalmol</source>. <year>2018</year>;<volume>136</volume>: <fpage>729</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2018.1538</pub-id><?supplied-pmid 29801085?><pub-id pub-id-type="pmid">29801085</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Joseph</surname><given-names>S</given-names></name>, <name><surname>Kim</surname><given-names>R</given-names></name>, <name><surname>Ravindran</surname><given-names>RD</given-names></name>, <name><surname>Fletcher</surname><given-names>AE</given-names></name>, <name><surname>Ravilla</surname><given-names>TD</given-names></name>. <article-title>Effectiveness of Teleretinal Imaging–Based Hospital Referral Compared With Universal Referral in Identifying Diabetic Retinopathy: A Cluster Randomized Clinical Trial</article-title>. <source>JAMA Ophthalmol</source>. <year>2019</year>;<volume>137</volume>: <fpage>786</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2019.1070</pub-id><?supplied-pmid 31070699?><pub-id pub-id-type="pmid">31070699</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Antonetti</surname><given-names>DA</given-names></name>, <name><surname>Gardner</surname><given-names>TW</given-names></name>. <article-title>Diabetic Retinopathy</article-title>. <source>The New England Journal of Medicine</source>. <year>2012</year>; <volume>13</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMra1005073</pub-id><?supplied-pmid 22455417?><pub-id pub-id-type="pmid">22455417</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Daskivich</surname><given-names>LP</given-names></name>, <name><surname>Vasquez</surname><given-names>C</given-names></name>, <name><surname>Martinez</surname><given-names>C</given-names><suffix>Jr</suffix></name>, <name><surname>Tseng</surname><given-names>C-H</given-names></name>, <name><surname>Mangione</surname><given-names>CM</given-names></name>. <article-title>Implementation and Evaluation of a Large-Scale Teleretinal Diabetic Retinopathy Screening Program in the Los Angeles County Department of Health Services</article-title>. <source>JAMA Internal Medicine</source>. <year>2017</year>;<volume>177</volume>: <fpage>642</fpage>–<lpage>649</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamainternmed.2017.0204</pub-id>
<?supplied-pmid 28346590?><pub-id pub-id-type="pmid">28346590</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Vujosevic</surname><given-names>S</given-names></name>, <name><surname>Benetti</surname><given-names>E</given-names></name>, <name><surname>Massignan</surname><given-names>F</given-names></name>, <name><surname>Pilotto</surname><given-names>E</given-names></name>, <name><surname>Varano</surname><given-names>M</given-names></name>, <name><surname>Cavarzeran</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Screening for Diabetic Retinopathy: 1 and 3 Nonmydriatic 45-degree Digital Fundus Photographs vs 7 Standard Early Treatment Diabetic Retinopathy Study Fields</article-title>. <source>American Journal of Ophthalmology</source>. <year>2009</year>;<volume>148</volume>: <fpage>111</fpage>–<lpage>118</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2009.02.031</pub-id>
<?supplied-pmid 19406376?><pub-id pub-id-type="pmid">19406376</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Shi</surname><given-names>L</given-names></name>, <name><surname>Wu</surname><given-names>H</given-names></name>, <name><surname>Dong</surname><given-names>J</given-names></name>, <name><surname>Jiang</surname><given-names>K</given-names></name>, <name><surname>Lu</surname><given-names>X</given-names></name>, <name><surname>Shi</surname><given-names>J</given-names></name>. <article-title>Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis</article-title>. <source>Br J Ophthalmol</source>. <year>2015</year>;<volume>99</volume>: <fpage>823</fpage>–<lpage>831</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bjophthalmol-2014-305631</pub-id>
<?supplied-pmid 25563767?><pub-id pub-id-type="pmid">25563767</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Chu</surname><given-names>Z</given-names></name>, <name><surname>Lin</surname><given-names>J</given-names></name>, <name><surname>Gao</surname><given-names>C</given-names></name>, <name><surname>Xin</surname><given-names>C</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Chen</surname><given-names>C-L</given-names></name>, <etal>et al</etal>. <article-title>Quantitative assessment of the retinal microvasculature using optical coherence tomography angiography</article-title>. <source>J Biomed Opt</source>. <year>2016</year>;<volume>21</volume>: <fpage>066008</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1117/1.JBO.21.6.066008</pub-id><?supplied-pmid 27286188?><pub-id pub-id-type="pmid">27286188</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Ashimatey</surname><given-names>BS</given-names></name>, <name><surname>Green</surname><given-names>KM</given-names></name>, <name><surname>Chu</surname><given-names>Z</given-names></name>, <name><surname>Wang</surname><given-names>RK</given-names></name>, <name><surname>Kashani</surname><given-names>AH</given-names></name>. <article-title>Impaired Retinal Vascular Reactivity in Diabetic Retinopathy as Assessed by Optical Coherence Tomography Angiography</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2019</year>;<volume>60</volume>: <fpage>2468</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1167/iovs.18-26417</pub-id><?supplied-pmid 31173077?><pub-id pub-id-type="pmid">31173077</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Green</surname><given-names>KM</given-names></name>, <name><surname>Toy</surname><given-names>BC</given-names></name>, <name><surname>Ashimatey</surname><given-names>BS</given-names></name>, <name><surname>Mustafi</surname><given-names>D</given-names></name>, <name><surname>Jennelle</surname><given-names>RL</given-names></name>, <name><surname>Astrahan</surname><given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Quantifying Subclinical and Longitudinal Microvascular Changes Following Episcleral Plaque Brachytherapy Using Spectral Domain–Optical Coherence Tomography Angiography</article-title>. <source>Journal of VitreoRetinal Diseases</source>. <year>2020</year>; 247412642093619. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/2474126420936199</pub-id><?supplied-pmid 33409441?><pub-id pub-id-type="pmid">33409441</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Abràmoff</surname><given-names>MD</given-names></name>, <name><surname>Folk</surname><given-names>JC</given-names></name>, <name><surname>Han</surname><given-names>DP</given-names></name>, <name><surname>Walker</surname><given-names>JD</given-names></name>, <name><surname>Williams</surname><given-names>DF</given-names></name>, <name><surname>Russell</surname><given-names>SR</given-names></name>, <etal>et al</etal>. <article-title>Automated Analysis of Retinal Images for Detection of Referable Diabetic Retinopathy</article-title>. <source>JAMA Ophthalmol</source>. <year>2013</year>;<volume>131</volume>: <fpage>351</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2013.1743</pub-id><?supplied-pmid 23494039?><pub-id pub-id-type="pmid">23494039</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Klein</surname><given-names>R</given-names></name>, <name><surname>Klein</surname><given-names>BEK</given-names></name>, <name><surname>Moss</surname><given-names>SE</given-names></name>, <name><surname>Davis</surname><given-names>MD</given-names></name>, <name><surname>DeMets</surname><given-names>DL</given-names></name>. <article-title>The Wisconsin Epidemiologic Study of Diabetic Retinopathy: III. Prevalence and Risk of Diabetic Retinopathy When Age at Diagnosis Is 30 or More Years</article-title>. <source>Archives of Ophthalmology</source>. <year>1984</year>;<volume>102</volume>: <fpage>527</fpage>–<lpage>532</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/archopht.1984.01040030405011</pub-id>
<?supplied-pmid 6367725?><pub-id pub-id-type="pmid">6367725</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>DeLong</surname><given-names>ER</given-names></name>, <name><surname>DeLong</surname><given-names>DM</given-names></name>, <name><surname>Clarke-Pearson</surname><given-names>DL</given-names></name>. <article-title>Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach</article-title>. <source>Biometrics</source>. <year>1988</year>;<volume>44</volume>: <fpage>837</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2307/2531595</pub-id><?supplied-pmid 3203132?><pub-id pub-id-type="pmid">3203132</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>An</surname><given-names>D</given-names></name>, <name><surname>Balaratnasingam</surname><given-names>C</given-names></name>, <name><surname>Heisler</surname><given-names>M</given-names></name>, <name><surname>Francke</surname><given-names>A</given-names></name>, <name><surname>Ju</surname><given-names>M</given-names></name>, <name><surname>McAllister</surname><given-names>IL</given-names></name>, <etal>et al</etal>. <article-title>Quantitative comparisons between optical coherence tomography angiography and matched histology in the human eye</article-title>. <source>Experimental Eye Research</source>. <year>2018</year>;<volume>170</volume>: <fpage>13</fpage>–<lpage>19</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.exer.2018.02.006</pub-id>
<?supplied-pmid 29448042?><pub-id pub-id-type="pmid">29448042</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Pappuru</surname><given-names>RKR</given-names></name>, <name><surname>Ribeiro</surname><given-names>L</given-names></name>, <name><surname>Lobo</surname><given-names>C</given-names></name>, <name><surname>Alves</surname><given-names>D</given-names></name>, <name><surname>Cunha-Vaz</surname><given-names>J</given-names></name>. <article-title>Microaneurysm turnover is a predictor of diabetic retinopathy progression</article-title>. <source>Br J Ophthalmol</source>. <year>2019</year>;<volume>103</volume>: <fpage>222</fpage>–<lpage>226</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bjophthalmol-2018-311887</pub-id>
<?supplied-pmid 29699981?><pub-id pub-id-type="pmid">29699981</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>König</surname><given-names>IR</given-names></name>, <name><surname>Malley</surname><given-names>JD</given-names></name>, <name><surname>Weimar</surname><given-names>C</given-names></name>, <name><surname>Diener</surname><given-names>H-C</given-names></name>, <name><surname>Ziegler</surname><given-names>A</given-names></name>, <collab>on behalf of the German Stroke Study Collaboration</collab>. <article-title>Practical experiences on the necessity of external validation</article-title>. <source>Statist Med</source>. <year>2007</year>;<volume>26</volume>: <fpage>5499</fpage>–<lpage>5511</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.3069</pub-id>
<?supplied-pmid 17907249?><pub-id pub-id-type="pmid">17907249</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Ashraf</surname><given-names>M</given-names></name>, <name><surname>Nesper</surname><given-names>PL</given-names></name>, <name><surname>Jampol</surname><given-names>LM</given-names></name>, <name><surname>Yu</surname><given-names>F</given-names></name>, <name><surname>Fawzi</surname><given-names>AA</given-names></name>. <article-title>Statistical Model of Optical Coherence Tomography Angiography Parameters That Correlate With Severity of Diabetic Retinopathy</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2018</year>;<volume>59</volume>: <fpage>4292</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1167/iovs.18-24142</pub-id><?supplied-pmid 30167660?><pub-id pub-id-type="pmid">30167660</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Jung</surname><given-names>JJ</given-names></name>, <name><surname>Yu</surname><given-names>DJG</given-names></name>, <name><surname>Zeng</surname><given-names>A</given-names></name>, <name><surname>Chen</surname><given-names>MH</given-names></name>, <name><surname>Shi</surname><given-names>Y</given-names></name>, <name><surname>Nassisi</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Correlation of Quantitative Measurements with Diabetic Disease Severity Using Multiple En Face OCT Angiography Image Averaging</article-title>. <source>Ophthalmology Retina</source>. <year>2020</year>;<volume>4</volume>: <fpage>1069</fpage>–<lpage>1082</lpage>.<pub-id pub-id-type="pmid">32389888</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Bhanushali</surname><given-names>D</given-names></name>, <name><surname>Anegondi</surname><given-names>N</given-names></name>, <name><surname>Gadde</surname><given-names>SGK</given-names></name>, <name><surname>Srinivasan</surname><given-names>P</given-names></name>, <name><surname>Chidambara</surname><given-names>L</given-names></name>, <name><surname>Yadav</surname><given-names>NK</given-names></name>, <etal>et al</etal>. <article-title>Linking Retinal Microvasculature Features With Severity of Diabetic Retinopathy Using Optical Coherence Tomography Angiography</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2016</year>;<volume>57</volume>: <fpage>OCT519</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1167/iovs.15-18901</pub-id><?supplied-pmid 27472275?><pub-id pub-id-type="pmid">27472275</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Binotti</surname><given-names>WW</given-names></name>, <name><surname>Romano</surname><given-names>AC</given-names></name>. <article-title>Projection-Resolved Optical Coherence Tomography Angiography Parameters to Determine Severity in Diabetic Retinopathy</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2019</year>;<volume>60</volume>: <fpage>1321</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1167/iovs.18-24154</pub-id><?supplied-pmid 30933259?><pub-id pub-id-type="pmid">30933259</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Kaizu</surname><given-names>Y</given-names></name>, <name><surname>Nakao</surname><given-names>S</given-names></name>, <name><surname>Arima</surname><given-names>M</given-names></name>, <name><surname>Hayami</surname><given-names>T</given-names></name>, <name><surname>Wada</surname><given-names>I</given-names></name>, <name><surname>Yamaguchi</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Flow Density in Optical Coherence Tomography Angiography is Useful for Retinopathy Diagnosis in Diabetic Patients</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>: <fpage>8668</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-019-45194-z</pub-id><?supplied-pmid 31209251?><pub-id pub-id-type="pmid">31209251</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Kaizu</surname><given-names>Y</given-names></name>, <name><surname>Nakao</surname><given-names>S</given-names></name>, <name><surname>Yoshida</surname><given-names>S</given-names></name>, <name><surname>Hayami</surname><given-names>T</given-names></name>, <name><surname>Arima</surname><given-names>M</given-names></name>, <name><surname>Yamaguchi</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Optical Coherence Tomography Angiography Reveals Spatial Bias of Macular Capillary Dropout in Diabetic Retinopathy</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2017</year>;<volume>58</volume>: <fpage>4889</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1167/iovs.17-22306</pub-id><?supplied-pmid 28973335?><pub-id pub-id-type="pmid">28973335</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Al-Sheikh</surname><given-names>M</given-names></name>, <name><surname>Akil</surname><given-names>H</given-names></name>, <name><surname>Pfau</surname><given-names>M</given-names></name>, <name><surname>Sadda</surname><given-names>SR</given-names></name>. <article-title>Swept-Source OCT Angiography Imaging of the Foveal Avascular Zone and Macular Capillary Network Density in Diabetic Retinopathy</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2016</year>;<volume>57</volume>: <fpage>3907</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1167/iovs.16-19570</pub-id><?supplied-pmid 27472076?><pub-id pub-id-type="pmid">27472076</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Ishibazawa</surname><given-names>A</given-names></name>, <name><surname>Nagaoka</surname><given-names>T</given-names></name>, <name><surname>Takahashi</surname><given-names>A</given-names></name>, <name><surname>Omae</surname><given-names>T</given-names></name>, <name><surname>Tani</surname><given-names>T</given-names></name>, <name><surname>Sogawa</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot Study</article-title>. <source>American Journal of Ophthalmology</source>. <year>2015</year>;<volume>160</volume>: <fpage>35</fpage>–<lpage>44.e1</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2015.04.021</pub-id>
<?supplied-pmid 25896459?><pub-id pub-id-type="pmid">25896459</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>C</given-names></name>, <name><surname>Yan</surname><given-names>S</given-names></name>, <name><surname>Du</surname><given-names>M</given-names></name>, <name><surname>Zhao</surname><given-names>H</given-names></name>, <name><surname>Shao</surname><given-names>L</given-names></name>, <name><surname>Hu</surname><given-names>Y</given-names></name>. <article-title>Assessment of capillary dropout in the superficial retinal capillary plexus by optical coherence tomography angiography in the early stage of diabetic retinopathy</article-title>. <source>BMC Ophthalmol</source>. <year>2018</year>;<volume>18</volume>: <fpage>113</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12886-018-0778-2</pub-id><?supplied-pmid 29739379?><pub-id pub-id-type="pmid">29739379</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Hwang</surname><given-names>TS</given-names></name>, <name><surname>Hagag</surname><given-names>AM</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Smith</surname><given-names>A</given-names></name>, <name><surname>Wilson</surname><given-names>DJ</given-names></name>, <etal>et al</etal>. <article-title>Automated Quantification of Nonperfusion Areas in 3 Vascular Plexuses With Optical Coherence Tomography Angiography in Eyes of Patients With Diabetes</article-title>. <source>JAMA Ophthalmol</source>. <year>2018</year>;<volume>136</volume>: <fpage>929</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2018.2257</pub-id><?supplied-pmid 29902297?><pub-id pub-id-type="pmid">29902297</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Sarraf</surname><given-names>D</given-names></name>, <name><surname>Sadda</surname><given-names>S</given-names></name>. <article-title>Pearls and Pitfalls of Optical Coherence Tomography Angiography Image Interpretation</article-title>. <source>JAMA Ophthalmol</source>. <year>2020</year>;<volume>138</volume>: <fpage>126</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2019.5099</pub-id><?supplied-pmid 31804665?><pub-id pub-id-type="pmid">31804665</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Lei</surname><given-names>J</given-names></name>, <name><surname>Durbin</surname><given-names>MK</given-names></name>, <name><surname>Shi</surname><given-names>Y</given-names></name>, <name><surname>Uji</surname><given-names>A</given-names></name>, <name><surname>Balasubramanian</surname><given-names>S</given-names></name>, <name><surname>Baghdasaryan</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Repeatability and Reproducibility of Superficial Macular Retinal Vessel Density Measurements Using Optical Coherence Tomography Angiography En Face Images</article-title>. <source>JAMA Ophthalmol</source>. <year>2017</year>;<volume>135</volume>: <fpage>1092</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2017.3431</pub-id><?supplied-pmid 28910435?><pub-id pub-id-type="pmid">28910435</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0262996.ref045">
                <label>45</label>
                <mixed-citation publication-type="journal"><name><surname>Llanas</surname><given-names>S</given-names></name>, <name><surname>Linderman</surname><given-names>RE</given-names></name>, <name><surname>Chen</surname><given-names>FK</given-names></name>, <name><surname>Carroll</surname><given-names>J</given-names></name>. <article-title>Assessing the Use of Incorrectly Scaled Optical Coherence Tomography Angiography Images in Peer-Reviewed Studies: A Systematic Review</article-title>. <source>JAMA Ophthalmol</source>. <year>2020</year>;<volume>138</volume>: <fpage>86</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2019.4821</pub-id><?supplied-pmid 31774456?><pub-id pub-id-type="pmid">31774456</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
